Pharmacotherapy of Zollinger-Ellison syndrome

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 307-321

  Ito, Tetsuhide ^a,b   Igarashi, Hisato ^a,b   Uehara, Hirotsugu ^b   Jensen, Robert T ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acid hypersecretion; Chemotherapy; Gastrinoma; Multiple endocrine neoplasia type 1; Neuroendocrine tumor; Pancreatic endocrine tumor; Peptide radio receptor therapy; Proton pump inhibitor; Zollinger Ellison syndrome

Indexed keywords

ANGIOPEPTIN; CAPECITABINE; CIMETIDINE; CISPLATIN; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ESOMEPRAZOLE; EVEROLIMUS; FAMOTIDINE; FLUOROURACIL; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON; KETOCONAZOLE; LANSOPRAZOLE; MIFEPRISTONE; OCTREOTIDE; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PENTETREOTIDE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SECRETIN; SOMATOSTATIN; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VINCRISTINE;

ACHLORHYDRIA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLELITHIASIS; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; ENDOSCOPIC ECHOGRAPHY; FLU LIKE SYNDROME; GASTRECTOMY BILLROTH II; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROESOPHAGEAL REFLUX; GYNECOMASTIA; HEMATOLOGIC DISEASE; HIGHLY SELECTIVE VAGOTOMY; HUMAN; HYPERGASTRINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPOMAGNESEMIA; IMPOTENCE; INSULINOMA; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PEPTIC ULCER; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PROGNOSIS; PROLACTINOMA; PROVOCATION TEST; RADIOFREQUENCY ABLATION; REVIEW; SELECTED INTERNAL RADIATION THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEATORRHEA; STOMACH ACID SECRETION; STOMATITIS; TOTAL STOMACH RESECTION; TUMOR LOCALIZATION; VAGOTOMY; ZOLLINGER ELLISON SYNDROME;

ANIMALS; GASTRIC ACID; GASTRINOMA; HUMANS; HYPERPARATHYROIDISM; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROTON PUMP INHIBITORS; ZOLLINGER-ELLISON SYNDROME;

EID: 84873389357     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.767332     Document Type: Review

References (169)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-28
2. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome: Correlation with clinical expression, tumor extent and role in diagnosis - A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001;80:189-222 (Pubitemid 32466460)
3. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: Clinical presentation in 261 patients. Medicine (Baltimore) 2000;79:379-411
4. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory States: Recent insights and advances. Curr Gastroenterol Rep 2009;11:433-41
5. Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In: Go VLW, Brooks FA, DiMagno EP, et al. editors. The exocrine pancreas: Biology, pathobiology and disease. Raven Press; New York: 1986. p. 727-44
6. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: A comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009;46:13-106
7. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92
8. Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119
9. Riccardi F, Rizzo M, Festino L, et al. Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets 2012;16(SUPPL2):S91-102
10. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: Diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004;6:454-63 (Pubitemid 39591825)
11. Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother 2009;10:1145-57
12. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-82
13. Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005;7:114-21 (Pubitemid 40796696)
14. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Cancer 2006;4:148-53 (Pubitemid 44265371)
15. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001;234:495-506 (Pubitemid 32946712)
16. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-Type 1 (MEN1). Surg Oncol 2003;12:145-51 (Pubitemid 37289019)
17. MacFarlane MP, Fraker DL, Alexander HR, et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-Type 1. Surgery 1995;118:973-80
18. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004;240:757-73 (Pubitemid 39425767)
19. Jensen RT, Berna MJ, Bingham MD, et al. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008;113(7 Suppl):1807-43
20. Gibril F, Chen Y-J, Schrump DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-81 (Pubitemid 36337758)
21. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998;243:477-88 (Pubitemid 28312244)
22. Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004;83:43-83 (Pubitemid 38124855)
23. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-Like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: Identification of risk factors. J Clin Endocrinol Metab 2008;93:1582-91 (Pubitemid 351656492)
24. Asgharian B, Chen YJ, Patronas NJ, et al. Meningiomas may be a component tumor of MEN1. Clin Cancer Res 2004;10:869-80
25. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, et al. Liver transplantation and neuroendocrine tumors: Lessons from a single centre experience and from the literature review. Transpl Int 2010;23:668-78
26. Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011;17:1343-53
27. Nieto JM, Pisegna Jr. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006;7:169-75 (Pubitemid 43263256)
28. Auernhammer CJ, Goke B. Medical treatment of gastrinomas. Wien Klin Wochenschr 2007;119:609-15 (Pubitemid 350060658)
29. Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol 2012;18:5495-503
30. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: Dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012;10:199-202
31. Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 2007;119:573-8 (Pubitemid 350060665)
32. Berna MJ, Hoffmann KM, Long SHet al.Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006;85:331-64 (Pubitemid 44772672)
33. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006;85:295-330 (Pubitemid 44772671)
34. Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2012;10:126-30
35. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol 2012;24:46-55
36. Pavel M, Baudin E, Couvelard A, et al. Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-76
37. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): Recent insights and advances. J Gastroenterol 2012;47:941-60
38. Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2012;41:119-31
39. Kulke MH, Benson AB III, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-64
40. Dasanu CA, Majumder S, Gopal S, et al. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors. Expert Opin Pharmacother 2012;13:461-71
41. Srirajaskanthan R, Toumpanakis C, Meyer T, et al. Review article: Future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. Aliment Pharmacol Ther 2009;29:1143-54
42. Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-5
43. Feldmann G, Bisht S, Schutte U, et al. Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opin Pharmacother 2012;13(14):2073-84
44. Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012;17:747-55
45. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:2963-70
46. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: An analysis of the UNOS database. Arch Surg 2011;146:953-8
47. Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol 2012;2012:471203
48. van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2012; Epub ahead of print
49. Teunissen JJ, Kwekkeboom DJ, Valkema R, et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18(SUPPL1):S27-51
50. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30
51. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndromë Aliment Pharmacol Ther 2001;15:1555-61 (Pubitemid 32912397)
52. Wong H, Yau T, Chan P, et al. PPI-Delayed diagnosis of gastrinoma: Oncologic victim of pharmacologic success. Pathol Oncol Res 2010;16:87-91
53. Baldwin CM, Keam SJ. Rabeprazole: A review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401
54. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000;40:52-62
55. Vachhani R, Olds G, Velanovich V. Esomeprazole: A proton pump inhibitor. Expert Rev Gastroenterol Hepatol 2009;3:15-27
56. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103:1498-508
57. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with the Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:394-404
58. Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993;17:468-80 (Pubitemid 23228400)
59. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993;38:245-56 (Pubitemid 23054357)
60. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: A prospective study. Gastroenterology 1988;94:294-9 (Pubitemid 18054764)
61. Collen MJ, Howard JM, McArthur KE, et al. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 1984;100:52-8 (Pubitemid 14219129)
62. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, editors. Surgical endocrinology: Clinical syndromes. Lippincott Williams & Wilkins; Philadelphia: 2001. p. 291-344
63. Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-78
64. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842-60 (Pubitemid 351783299)
65. Howard JM, Chremos AN, Collen MJ, et al. Famotidine, a new, potent, long-Acting histamine H2-receptor antagonist: Comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985;88:1026-33 (Pubitemid 15105898)
66. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison: A prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993;7:597-610 (Pubitemid 24035169)
67. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: A 13-year prospective study. Clin Gastroenterol Hepatol 2005;3:39-48 (Pubitemid 40092942)
68. Weber HC, Venzon DJ, Jensen RT, et al. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology 1997;112:84-91 (Pubitemid 27008989)
69. Murugesan SV, Varro A, Pritchard DM. Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009;29:1055-68
70. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012;41:508-11
71. Ito T, Igarashi H, Jensen RT. Serum pancreastatin: The long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012;41:505-7
72. Dhillo WS, Jayasena CN, Lewis CJ, et al. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem 2006;43:153-5 (Pubitemid 43332337)
73. Frucht H, Howard JM, Stark HA, et al. Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. Am J Med 1989;87:528-36 (Pubitemid 19274756)
74. Shibata C, Funayama Y, Fukushima K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008;12:344-9
75. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-Term cure in patients with Zollinger-Ellison syndrome: The best approach. Ann Intern Med 1993;119:199-206 (Pubitemid 23327619)
76. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperaparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): Longterm outcome of a more virulent form of HPTAnn Surg 2008;247:501-10
77. Goldman JA, Blanton WP, Hay DW, et al. Case report: False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009;7:600-2
78. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: Well-Differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52
79. Metz DC, Buchanan M, Purich E, et al. A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome. Aliment Pharmacol Ther 2001;15:669-76 (Pubitemid 32385872)
80. Long SH, Berna MJ, Thill M, et al. Secretin-receptor and secretin-receptor-Variant expression in gastrinomas: Correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 2007;92:4394-402 (Pubitemid 350074762)
81. Jensen RT. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. In: Olbe L, editor. Milestones in drug therapy. Birkhauser Verlag AG Publish. Co; Basel, Switzerland: 1999. p. 205-21
82. Franz RC, Penzhorn HO. Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndromë S Afr J Surg 2007;45:58-60
83. Jensen RT, Collen MJ, Allende HD, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983;308:883-7 (Pubitemid 13116544)
84. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al. editors. The pancreas: Biology, pathobiology and disease. Raven Press Publishing Co; New York: 1993. p. 931-78
85. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on Acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric Acid hypersecretion. Am J Gastroenterol 2007;102:2648-54 (Pubitemid 350179329)
86. McKeage K, Blick SK, Croxtall JD, et al. Esomeprazole: A review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68:1571-607 (Pubitemid 352001193)
87. Morocutti A, Merrouche M, Bjaaland T, et al. An open-Label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther 2006;24:1439-44 (Pubitemid 44657120)
88. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001;96:3274-80 (Pubitemid 34016648)
89. Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006;23:437-44 (Pubitemid 43382024)
90. Jensen RT. Consequences of long-Term proton pump blockade: Highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4-19
91. Ito T, Jensen RT. Association of long-Term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin b(12), iron, and magnesium. Curr Gastroenterol Rep 2010;12:448-57
92. Termanini B, Gibril F, Sutliff VE III, et al. Effect of long-Term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30 (Pubitemid 28274845)
93. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-Term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-21 (Pubitemid 351614880)
94. Stewart CA, Termanini B, Sutliff VE, et al. Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-Term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12:83-98 (Pubitemid 28057410)
95. Yang YX, Lewis JD, Epstein S, et al. Long-Term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53 (Pubitemid 46021498)
96. Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: An increasing problem? Results of a prospective case-Series and systematic review of the literature. Dig Liver Dis 2011;43:380-5
97. Vakil N. Prescribing proton pump inhibitors: Is it time to pause and rethink? Drugs 2012;72:437-45
98. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-Acquired pneumoniä A meta-Analysis. Expert Rev Clin Pharmacol 2012;5:337-44
99. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-Like cells: Insights from patients with sporadic gastrinomas. Gastroenterology 2002;123:68-85 (Pubitemid 34747527)
100. Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990;99:943-50 (Pubitemid 20338449)
101. Orbuch M, Venzon DJ, Lubensky IA, et al. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1996;41:604-13 (Pubitemid 26116417)
102. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990;98:341-6 (Pubitemid 20037915)
103. Granberg D, Jacobsson H, Oberg K, et al. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: A case report. Digestion 2008;77:92-5 (Pubitemid 351556386)
104. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983;84:108-13 (Pubitemid 13198296)
105. Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: Response to cinacalcet and its relationship with the calcium-Sensing receptor gene variant Arg990Gly. Eur J Endocrinol 2012;167:157-64
106. Moyes VJ, Monson JP, Chew SL, et al. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010;2010:906163
107. Stewart CA, Termanini B, Sutliff VE, et al. Management of Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 1997;176:224-33
108. Matok I, Gorodischer R, Koren G, et al. The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 2010;50:81-7
109. Gill SK, O'Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: A meta-Analysis. Dig Dis Sci 2009;54:1835-8
110. Gill SK, O'Brien L, Einarson TR, et al. The safety of proton pump inhibitors (PPIs) in pregnancy: A meta-Analysis. Am J Gastroenterol 2009;104:1541-5
111. Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012;57:699-705
112. Harper MA, McVeigh JE, Thompson W, et al. Successful pregnancy in association with Zollinger-Ellison syndrome. Am J Obstet Gynecol 1995;173:863-4
113. Mayer A, Sheiner E, Holcberg G. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet 2007;276:171-3 (Pubitemid 47022945)
114. Saeed ZA, Norton JA, Frank WO, et al. Parenteral antisecretory drug therapy in patients with Zollinger- Ellison syndrome. Gastroenterology 1989;96:1393-402 (Pubitemid 19138678)
115. Fraker DL, Norton JA, Saeed ZA, et al. A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome. Surgery 1988;104:1054-63 (Pubitemid 19011986)
116. Vinayek R, Hahne WF, Euler AR, et al. Parenteral control of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993;38:1857-65 (Pubitemid 23311938)
117. Vinayek R, Frucht H, London JF, et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990;99:10-16 (Pubitemid 20202484)
118. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000;118:696-704 (Pubitemid 30171619)
119. Pang SH, Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Ther Adv Gastroenterol 2010;3:11-22
120. Chiang HC, O'Dorisio TM, Huang SC, et al. Multiple hormone elevations in patients with Zollinger-Ellison syndrome: Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 1990;99:1565-75
121. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-30 (Pubitemid 29075250)
122. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986;315:1-5
123. Sreevathsa MR, Choudhury A. Long-Term survival in a patient with carcinoid syndrome receiving treatment for Zollinger-Ellison syndrome. Int Surg 2009;94:20-2
124. Morita Y, Suzuki S, Sakaguchi T, et al. Pancreatic neuroendocrine cell tumor secreting parathyroid hormone-related protein and gastrin: Report of a case. Surg Today 2010;40:1192-6
125. Doppman JL, Nieman LK, Cutler GB. Jr., et al. Adrenocorticotropic hormone-Secreting islet cell tumors: Are they always malignant? Radiology 1994;190:59-64
126. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 1988;319:605-7
127. Norton JA, Melcher ML, Gibril F, et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery. Surgery 2004;136:1267-74 (Pubitemid 39647544)
128. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-Type 1. Am J Med 1994;97:436-44 (Pubitemid 24345595)
129. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011
130. Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. Discov Med 2012;13:171-9
131. de Herder WW, van Schaik E, Kwekkeboom D, et al. New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 2011;75:277-84
132. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004;36:S106-20 (Pubitemid 41115498)
133. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997;15:2420-31 (Pubitemid 27251146)
134. Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: Comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol 1984;143:585-9 (Pubitemid 14067875)
135. Alexander RA, Jensen RT. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. Lippincott Williams & Wilkins; Philadelphia: 2001. p. 1788-813
136. Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med 1986;105:841-7 (Pubitemid 17201757)
137. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: Localization by means of selective intraarterial injection of secretin. Radiology 1990;174:25-9 (Pubitemid 20017077)
138. Gibril F, Doppman JL, Chang R, et al. Metastatic gastrinomas: Localization with selective arterial injection of secretin. Radiology 1996;198:77-84 (Pubitemid 26008244)
139. Thom AK, Norton JA, Axiotis CA, et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991;110:1086-93
140. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004;239:617-26 (Pubitemid 38525632)
141. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988;94:1326-34
142. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007;21:43-68
143. Frucht H, Doppman JL, Norton JA, et al. Gastrinomas: Comparison of MR Imaging with CT, angiography and US. Radiology 1989;171:713-17
144. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study. Ann Intern Med 1996;125:26-34
145. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040-53 (Pubitemid 28108739)
146. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, editors. Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. John Libbey Eurotext Publishing Co; Paris, France: 1999. p. 192-219
147. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244:410-19
148. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:131-44 (Pubitemid 46421904)
149. Strosberg JR, Fine RL, Choi J, et al. First-Line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75
150. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (High-Grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799-800
151. Nilsson O, Van Cutsem E, Delle Fave G, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212-15 (Pubitemid 46361055)
152. Plockinger U, Wiedenmann B. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007;21:145-62
153. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
154. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005;19:675-97 (Pubitemid 41614116)
155. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32
156. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009;72:517-28
157. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585-94 (Pubitemid 41447720)
158. Nazario J, Gupta S. Transarterial liver-Directed therapies of neuroendocrine hepatic metastases. Semin Oncol 2010;37:118-26
159. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010;16:163-75
160. Deleporte A, Flamen P, Hendlisz A. State of the art: Radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother 2010;11:579-86
161. Vyleta M, Coldwell D. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011;2011:785315
162. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62 (Pubitemid 46179465)
163. Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-Term stabilization of malignant gastrinomas. Cancer 2011;117:1377-85
164. de Wilde RF, Edil BH, Hruban RH, et al. Well-Differentiated pancreatic neuroendocrine tumors: From genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;9:199-208
165. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
166. Capurso G, Festa S, Valente R, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012;49:R37-50
167. Raymond E, Hobday T, Castellano D, et al. Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 2011;30(SUPPL1):19-26
168. Raut CP, Kulke MH. Targeted therapy in advanced well-Differentiated neuroendocrine tumors. Oncologist 2011;16:286-95
169. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13